CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Target Recruit Count
- 30
- Registration Number
- NCT00768911
- Locations
- ๐บ๐ธ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐บ๐ธUniversity of Kentucky Hospital, Lexington, Kentucky, United States
๐บ๐ธUniversity of Chicago Medical Center, Chicago, Illinois, United States
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Target Recruit Count
- 72
- Registration Number
- NCT00562419
- Locations
- ๐บ๐ธ
University of Kentucky, Lexington, Kentucky, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Target Recruit Count
- 40
- Registration Number
- NCT00374179
- Locations
- ๐บ๐ธ
Indiana University Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธSouth Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
๐บ๐ธInstitute for Drug Development, San Antonio, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath